PKU Market - Phenylketonuria Pipeline Therapeutics Landscape 2016 Report

Aug 26, 2016, 08:30 ET from RnR Market Research

PUNE, India, August 26, 2016 /PRNewswire/ --

RnRMarketResearch.com adds "Phenylketonuria (PKU) - Pipeline Review, H2 2016" market research report with comprehensive information on the therapeutic development for Phenylketonuria (PKU), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Phenylketonuria (PKU) and special features on late-stage and discontinued projects.

Complete report on H2 2016 pipeline review of Phenylketonuria (PKU) with 18 market data tables and 12 figures, spread across 51 pages is available at http://www.rnrmarketresearch.com/phenylketonuria-pku-pipeline-review-h2-2016-market-report.html .

Companies discussed in this Phenylketonuria (PKU) Pipeline Review, H2 2016 report include American Gene Technologies International Inc., BioMarin Pharmaceutical Inc., Codexis, Inc., Dimension Therapeutics, Inc., Erytech Pharma SA, SOM Innovation Biotech SL and Synthetic Biologics, Inc. Drug Profiles mentioned in this research are DTX-501, Gene Therapy for Phenylketonuria, pegvaliase, Proteins to Activate Phenylalanine Hydroxylase for Phenylketonuria, Recombinant Enzyme for Phenylketonuria, Recombinant Phenylalanine-4-Hydroxylase Replacement for Phenylketonuria, SOM-7400, SYN-200 and SYNB-2010.

Phenylketonuria (PKU) pipeline therapeutics constitutes close to 10 molecules. which approximately 10 molecules are developed by Companies.Global Markets Direct's latest report Phenylketonuria - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Phenylketonuria (PKU), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Phenylketonuria (PKU), is a rare inherited disorder that causes an amino acid called phenylalanine to build up in body. Symptoms include intellectual disability, psychiatric disorders, hyperactivity, skin rashes, poor bone strength and abnormally small head.   The molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 6 and 3 respectively.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=662435 . (This is a premium report priced at US$2000 for a single user License.)

The report also reviews key players involved in the therapeutic development for Phenylketonuria (PKU) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Phenylketonuria (PKU) and reviews pipeline therapeutics for Phenylketonuria (PKU) by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Phenylketonuria (PKU) therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Phenylketonuria (PKU) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Phenylketonuria (PKU).

Another newly published market research report titled on Nocturia - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Nocturia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nocturia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are Allergan Plc, Astellas Pharma Inc. and Vantia Therapeutics. Nocturia Pipeline market research report of 34 pages is available at http://www.rnrmarketresearch.com/nocturia-pipeline-review-h2-2016-market-report.html .

Explore more reports on Therapeutics.

About Us: 

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

Connect with Us:  

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

SOURCE RnR Market Research